- Exchange: NASDAQ CM
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
Galena Biopharma Inc
+ Add to WatchlistGALE:US
2.4100 USD 0.1200 5.24%As of 11:32:30 ET on 10/03/2013.
Snapshot for Galena Biopharma Inc (GALE)
| Open: | 2.5000 | Day's Range: | 2.3900 - 2.5800 | Volume: | 5,845,129 |
|---|---|---|---|---|---|
| Previous Close: | 2.2900 | 52wk Range: | 1.2300 - 3.0000 | 1-Yr Rtn: | +27.51% |
Key Statistics for GALE
| Current P/E Ratio (ttm) | 17.4464 |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | 1.0596 |
| Earnings Per Share (USD) (ttm) | 0.1400 |
| Est. EPS (USD) (12/2013) | -0.4390 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 256.19 |
| Shares Outstanding (M) | 104.89 |
| 30 Day Average Volume | 3,406,618 |
| Price/Book (mrq) | 13.3559 |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Dividend Ex-Date | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 11/13/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for GALE
Company Profile & Key Executives for GALE
Galena Biopharma, Inc. is a biopharmaceuticals company that develops late-stage oncology drugs. The Company develops therapies that activate cells in the immune system to seek out and eliminate tumor cells without harming healthy tissue.
| Mark J AhnPresident/CEO | Mark W SchwartzExec VP/COO |
| Rosemary MazanetExec VP/Chief Medical Officer | Ryan M DunlapDir:Finance/Secy/Controller |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
Advertisement
-
GALE News
-
Industry News
Advertisement
Sponsored Links
Advertisements
Rate this Page